Cubist Announces First Patient Dosed in Pivotal Global Phase 3 Trial of CXA-201 for Complicated Urinary Tract Infections

Cubist Pharmaceuticals, Inc. CBST today announced the initiation of a pivotal Phase 3 trial of CXA-201 in patients with complicated urinary tract infections. CXA-201 is being developed as a first-line intravenous therapy for the treatment of serious Gram-negative bacterial infections in the hospital, including those caused by multi-drug resistant Pseudomonas aeruginosa. This trial is the first of two planned multicenter, global, double-blind, randomized Phase 3 studies to compare the safety and efficacy of CXA-201 relative to the comparator, levofloxacin, in patients with cUTI.